R
Rakuten Medical
Developing precision cancer therapies using an investigational photoimmunotherapy platform to improve targeted treatment outcomes
About Rakuten Medical
Rakuten Medical is a biotechnology startup that operates in the healthcare industry, specifically in the field of cancer treatment. The company is developing a unique platform called Alluminox™, which is based on a cancer therapy known as photoimmunotherapy. This therapy was originally developed by Dr. Hisataka Kobayashi and his team from the National Cancer Institute in the United States.
The Alluminox™ platform is an investigational technology that includes a drug, a device, and other related components. Rakuten Medical's primary goal is to bring to market drugs and devices that treat various types of cancer using this platform. The company's mission is to provide an alternative solution in the fight against cancer, with the ultimate goal of conquering the disease.
Rakuten Medical aims to build a sustainable healthcare ecosystem that offers patients, regardless of their nationality or wealth, access to better cancer treatments. The company is committed to continuous innovation in order to develop and commercialize pioneering cancer treatments.
The business model of Rakuten Medical is based on the development and commercialization of its Alluminox™ platform. The company generates revenue by selling its innovative cancer treatment products to healthcare providers and patients.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2010
- Headquarters
- San Diego, United States
- Employees
- 131
- Open positions
- 7
- Dealroom signal
- 78.6/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Sep 2020
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Apr 2026 | $0 | — | Lotte | ↗ |
| CONVERTIBLEOther financing | Jan 2026 | $30M | — | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Rakuten Medical is 13K monthly website visits, down 7.1% over the last three months. Rakuten Medical's team grew 6.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Rakuten
Rakuten Capital
General Catalyst
Series B and later6 investors entered at this stage
SBI Group
SBI Investment
Dai-ichi Life Insurance
Mizuho Capital
Hikma Pharmaceuticals
Lotte
Other known investors1 additional known investor
National Cancer Institute (NCI)
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Rakuten Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Rakuten Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.